کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
8447193 1547184 2011 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Management of metastatic castration-resistant prostate cancer after first-line docetaxel
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Management of metastatic castration-resistant prostate cancer after first-line docetaxel
چکیده انگلیسی
Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 47, Issue 14, September 2011, Pages 2133-2142
نویسندگان
, ,